Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
86413 trials found · Page 72 of 4321
-
New shot aims to shield babies from dangerous RSV
Prevention CompletedThe purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), neutralizing antibody and antidrug antibody (ADA) response for TNM001 in infants entering their first RSV season.
Phase: PHASE2, PHASE3 • Sponsor: Zhuhai Trinomab Pharmaceutical Co., Ltd. • Aim: Prevention
Last updated Apr 20, 2026 16:17 UTC
-
New hope to keep advanced breast cancer at bay
Disease control Recruiting nowThis study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcutaneous use) compared with placebo in combination with Phesgo, as maintenance therapy, after induction therapy in participants with p…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Apr 14, 2026 13:08 UTC
-
New hope for aggressive brain cancer: dual immunotherapy trial launches
Disease control Recruiting nowThe purpose of this research study is to determine the safety and efficacy of administering a single intracerebral (within the brain) dose of investigational compounds called D2C7-immunotoxin (IT) and 2141-V11 in residual disease (within tumor margins) after surgery, followed by …
Phase: PHASE1, PHASE2 • Sponsor: Darell Bigner • Aim: Disease control
Last updated Apr 25, 2026 14:13 UTC
-
New drug trial offers hope for Brain-Injured newborns
Disease control Recruiting nowSovateltide (PMZ-1620; IRL-1620) is targeted to be used as a "Treatment for hypoxic-ischemic encephalopathy in neonates," which is a life-threatening condition. Sovateltide augments neuronal progenitor cell differentiation and better mitochondrial morphology and biogenesis to act…
Phase: PHASE2 • Sponsor: Pharmazz, Inc. • Aim: Disease control
Last updated Apr 09, 2026 19:32 UTC
-
One-Time gene infusion aims to halt rare, deadly heart disease
Disease control Recruiting nowThis is a single arm Phase 2 trial to evaluate the efficacy and safety of RP-A501, a recombinant adeno-associated virus serotype 9 (AAV9) containing the human lysosome-associated membrane protein 2 isoform B (LAMP2B) transgene, in male patients with Danon Disease.
Phase: PHASE2 • Sponsor: Rocket Pharmaceuticals Inc. • Aim: Disease control
Last updated Apr 20, 2026 16:18 UTC
-
New hope for Tough-to-Treat lymphoma: experimental combo battles standard therapies
Disease control Recruiting nowThis is an open label, multi-center, international, randomized phase III trial to compare the efficacy of Mosunetuzumab-Lenalidomide with investigator choices exclusively in R/R MZL patients. Patients with a proven diagnosis of EMZL, SMZL or NMZL subtypes and previously treated w…
Phase: PHASE3 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Apr 22, 2026 15:58 UTC
-
Beating heart cells injected during surgery to repair damaged hearts
Disease control OngoingThe purpose of this clinical study is to evaluate the feasibility, safety and efficacy of intramyocardial injection of human induce pluripotent stem cell-derived cardiomyocytes (HiCM-188) during coronary artery bypass grafting (CABG) surgery in patients with severe chronic ischem…
Phase: PHASE1, PHASE2 • Sponsor: HELP Therapeutics Co., Ltd. • Aim: Disease control
Last updated Apr 22, 2026 15:59 UTC
-
New transplant method aims to fight disease while reducing dangerous side effects
Disease control Recruiting nowIn this clinical trial, the investigators aim to apply CD62L depleted donor lymphocyte infusion (DLI) together with in vitro T cell depleted haploidentical hematopoietic stem cell transplantation (HSCT) to treat patients with malignant or non-malignant disease in need of HSCT. Th…
Phase: PHASE2 • Sponsor: Hong Kong Children's Hospital • Aim: Disease control
Last updated Apr 13, 2026 20:17 UTC
-
Scientists test 'Living Drug' to fight childhood cancers
Disease control Recruiting nowThis is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers.
Phase: PHASE1, PHASE2 • Sponsor: USWM CT, LLC • Aim: Disease control
Last updated Apr 16, 2026 12:47 UTC
-
Magic mushroom therapy shows promise in curbing alcohol abuse
Disease control CompletedNote: The trial is only eligible for citizens of Denmark. The purpose of this project is to assess the treatment efficacy of a single high dose of psilocybin administered within a protocol of psychological support to patients diagnosed with alcohol use disorder (AUD).
Phase: PHASE2 • Sponsor: Anders Fink-Jensen, MD, DMSci • Aim: Disease control
Last updated Apr 25, 2026 14:14 UTC
-
Brain-Delivered gene therapy tested to halt rare, Early-Onset dementia
Disease control Recruiting nowThe goal of this clinical study is to learn about an investigational gene therapy product called AVB-101, which is designed to treat a disease called Frontotemporal Dementia with Progranulin Mutations (FTD-GRN). FTD-GRN is an early-onset form of dementia, a progressive brain diso…
Phase: PHASE1, PHASE2 • Sponsor: AviadoBio Ltd • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
Breakthrough spinal implant study offers new hope for walking again
Disease control Recruiting nowThe purpose of this pre-market clinical study is to assess the preliminary safety and efficacy of the ARC Therapy using the ARC-IM Lumbar System at supporting mobility in participants who have previously received a spinal array and an implantable pulse generator (IPG) either thro…
Phase: NA • Sponsor: Ecole Polytechnique Fédérale de Lausanne • Aim: Disease control
Last updated Apr 22, 2026 15:59 UTC
-
New drug trial targets terrifying hallucinations in Alzheimer's patients
Symptom relief OngoingThis is a Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of KarXT in male and female subjects who are aged 55 to 90 years and have mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to…
Phase: PHASE3 • Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company • Aim: Symptom relief
Last updated Mar 30, 2026 14:32 UTC
-
Scientists test One-Shot gene fix for blood disorder
⭐️ CURE ⭐️ CompletedThe goal of this open label, single-arm clinical study is to learn about the safety and efficacy of CS-101 in treating β-thalassemia.
Phase: EARLY_PHASE1 • Sponsor: CorrectSequence Therapeutics Co., Ltd • Aim: ⭐️ CURE ⭐️
Last updated Mar 30, 2026 14:32 UTC
-
One-Shot gene therapy aims to halt rare, blinding eye disease in young people
Disease control Recruiting nowPhase 2/3 Pivotal Confirmatory Clinical Trial is a randomized, outcome assessor-masked, multicenter study, that will enroll fifty-one (51) subjects. Subjects will be enrolled in a 2:1 ratio to either the treatment group (n=34 subjects) or to an untreated control group (n=17 subje…
Phase: PHASE2, PHASE3 • Sponsor: Ocugen • Aim: Disease control
Last updated Apr 06, 2026 14:05 UTC
-
Game-Changer for cervical cancer: Same-Day Self-Test and AI triage could save millions
Prevention Recruiting nowIn May 2018, the World Health Organization (WHO) launched a strategy to eliminate cervical cancer. While this strategy seeks to achieve coverage of 70% in disease testing and 90% in treatment by 2030, it is estimated that these goals will not be achieved by most low- and middle- …
Sponsor: Atila Biosystems Inc. • Aim: Prevention
Last updated Apr 24, 2026 16:19 UTC
-
New Two-Drug combo injection shows promise for significant weight loss
Disease control CompletedThis study will look at how well the new medicine CagriSema helps people with excess body weight losing weight compared to a "dummy" medicine and a medicine called semaglutide. Participants will either get CagriSema, a dummy medicine or semaglutide. Which treatment participants g…
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Apr 23, 2026 12:43 UTC
-
First-Ever gene therapy injected directly into hearts of patients with inherited disease
Disease control Recruiting nowThis is a first-in-human, non-randomized, open-label study designed to evaluate the safety, tolerability, and pharmacodynamics (PD) of TN-201 in adult patients with symptomatic hypertrophic cardiomyopathy (HCM) caused by mutations in the MYBPC3 gene.
Phase: PHASE1, PHASE2 • Sponsor: Tenaya Therapeutics • Aim: Disease control
Last updated Apr 13, 2026 20:19 UTC
-
New drug trial aims to help people walk again after spinal injury
Disease control Recruiting nowA Randomized, Double-Blind, Placebo-Controlled Phase 1b/2a Study of NVG-291 in Spinal Cord Injury Subjects
Phase: PHASE1, PHASE2 • Sponsor: NervGen Pharma • Aim: Disease control
Last updated Apr 22, 2026 15:58 UTC
-
New drug combo aims to outperform standard care for tough blood cancers
Disease control Recruiting nowThe purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrutinib plus venetoclax is superior to VR wi…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Apr 06, 2026 14:16 UTC